Biosimilar infliximab use in paediatric IBD

Lisa Richmond; Lee Curtis; Victoria Garrick; Pam Rogers; Michelle Wilson; Rachel Tayler; Paul Henderson; Richard Hansen; David C. Wilson; Richard K. Russell

doi:10.1136/archdischild-2017-313404

Biosimilar infliximab use in paediatric IBD

Lisa Richmond, Lee Curtis, Victoria Garrick, Pam Rogers, Michelle Wilson, Rachel Tayler, Paul Henderson, Richard Hansen, David C. Wilson, Richard K. Russell

Research output: Contribution to journal › Article › peer-review

31 Citations (Scopus)

42 Downloads (Pure)

Abstract

Background: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease.

Methods: Prospective clinical data were collected from laboratory reports, electronic patient records and case notes of 40 patients starting Remsima for the first time. Disease activity scores together with blood and stool biomarkers were used to assess response.

Results: Our data set highlights that Remsima was associated with a significant clinical and biochemical improvement (p<0.01 or less for all parameters assessed) in Crohn’s disease post induction. There were no significant safety issues noted. The total cost saving was £47 800, representing a 38% reduction from originator.

Conclusion: We found that biosimilar infliximab is as effective as originator infliximab and its use is associated with significant cost savings.

Original language	English
Pages (from-to)	89-91
Number of pages	3
Journal	Archives of Disease in Childhood
Volume	103
Issue number	1
Early online date	7 Oct 2017
DOIs	https://doi.org/10.1136/archdischild-2017-313404
Publication status	Published - 13 Dec 2017

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1136/archdischild-2017-313404Licence: CC BY-NC

Final Published VersionFinal published version, 278 KBLicence: CC BY-NC

Cite this

@article{ba399222d40944ba9bcd879a72671196,

title = "Biosimilar infliximab use in paediatric IBD",

abstract = "Background: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. Methods: Prospective clinical data were collected from laboratory reports, electronic patient records and case notes of 40 patients starting Remsima for the first time. Disease activity scores together with blood and stool biomarkers were used to assess response. Results: Our data set highlights that Remsima was associated with a significant clinical and biochemical improvement (p<0.01 or less for all parameters assessed) in Crohn{\textquoteright}s disease post induction. There were no significant safety issues noted. The total cost saving was £47 800, representing a 38% reduction from originator. Conclusion: We found that biosimilar infliximab is as effective as originator infliximab and its use is associated with significant cost savings.",

author = "Lisa Richmond and Lee Curtis and Victoria Garrick and Pam Rogers and Michelle Wilson and Rachel Tayler and Paul Henderson and Richard Hansen and Wilson, {David C.} and Russell, {Richard K.}",

note = "Funding Information: Napp Pharmaceuticals provided financial support to help with this audit but did not have any influence on the data collection, analysis or conclusions drawn. RKR is supported by an NHS Research Scotland Senior Fellowship. The IBD team at RHC Glasgow is supported by the Catherine McEwan Foundation and Yorkhill IBD fund. The IBD teams in RHSC Edinburgh and University of Edinburgh are supported by the GI-Nutrition Research Fund, Child Life and Health, University of Edinburgh and the Edinburgh Children{\textquoteright}s Hospital Charity. RH and PH are supported by a Career Researcher Fellowship from NHS Research Scotland. We are grateful to Nadia Crockett, commodity manager at National Procurement Scotland, for advice on presenting costings related to originator and biosimilar infliximab. Publisher Copyright: {\textcopyright} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.",

year = "2017",

month = dec,

day = "13",

doi = "10.1136/archdischild-2017-313404",

language = "English",

volume = "103",

pages = "89--91",

journal = "Archives of Disease in Childhood",

issn = "0003-9888",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Biosimilar infliximab use in paediatric IBD

AU - Richmond, Lisa

AU - Curtis, Lee

AU - Garrick, Victoria

AU - Rogers, Pam

AU - Wilson, Michelle

AU - Tayler, Rachel

AU - Henderson, Paul

AU - Hansen, Richard

AU - Wilson, David C.

AU - Russell, Richard K.

N1 - Funding Information: Napp Pharmaceuticals provided financial support to help with this audit but did not have any influence on the data collection, analysis or conclusions drawn. RKR is supported by an NHS Research Scotland Senior Fellowship. The IBD team at RHC Glasgow is supported by the Catherine McEwan Foundation and Yorkhill IBD fund. The IBD teams in RHSC Edinburgh and University of Edinburgh are supported by the GI-Nutrition Research Fund, Child Life and Health, University of Edinburgh and the Edinburgh Children’s Hospital Charity. RH and PH are supported by a Career Researcher Fellowship from NHS Research Scotland. We are grateful to Nadia Crockett, commodity manager at National Procurement Scotland, for advice on presenting costings related to originator and biosimilar infliximab. Publisher Copyright: © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.

PY - 2017/12/13

Y1 - 2017/12/13

N2 - Background: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. Methods: Prospective clinical data were collected from laboratory reports, electronic patient records and case notes of 40 patients starting Remsima for the first time. Disease activity scores together with blood and stool biomarkers were used to assess response. Results: Our data set highlights that Remsima was associated with a significant clinical and biochemical improvement (p<0.01 or less for all parameters assessed) in Crohn’s disease post induction. There were no significant safety issues noted. The total cost saving was £47 800, representing a 38% reduction from originator. Conclusion: We found that biosimilar infliximab is as effective as originator infliximab and its use is associated with significant cost savings.

AB - Background: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. Methods: Prospective clinical data were collected from laboratory reports, electronic patient records and case notes of 40 patients starting Remsima for the first time. Disease activity scores together with blood and stool biomarkers were used to assess response. Results: Our data set highlights that Remsima was associated with a significant clinical and biochemical improvement (p<0.01 or less for all parameters assessed) in Crohn’s disease post induction. There were no significant safety issues noted. The total cost saving was £47 800, representing a 38% reduction from originator. Conclusion: We found that biosimilar infliximab is as effective as originator infliximab and its use is associated with significant cost savings.

UR - http://www.scopus.com/inward/record.url?scp=85039841447&partnerID=8YFLogxK

U2 - 10.1136/archdischild-2017-313404

DO - 10.1136/archdischild-2017-313404

M3 - Article

C2 - 28988215

AN - SCOPUS:85039841447

SN - 0003-9888

VL - 103

SP - 89

EP - 91

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

IS - 1

ER -

Biosimilar infliximab use in paediatric IBD

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this